UBS Group AG Has $11.01 Million Holdings in Kura Oncology, Inc. $KURA

UBS Group AG lifted its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 118.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,060,025 shares of the company’s stock after buying an additional 574,455 shares during the period. UBS Group AG’s holdings in Kura Oncology were worth $11,014,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Kura Oncology by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after buying an additional 2,977 shares in the last quarter. Strs Ohio acquired a new position in shares of Kura Oncology in the 1st quarter worth approximately $143,000. Legal & General Group Plc raised its holdings in shares of Kura Oncology by 35.1% in the 2nd quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock worth $421,000 after buying an additional 18,930 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Kura Oncology by 13.0% in the 2nd quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock worth $686,000 after buying an additional 13,690 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Kura Oncology by 244.5% in the 2nd quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock worth $1,343,000 after buying an additional 165,189 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Tuesday, April 21st. Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday. Mizuho dropped their price target on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Lake Street Capital assumed coverage on Kura Oncology in a report on Tuesday, April 14th. They set a “buy” rating and a $23.00 price target for the company. Finally, Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.38.

Kura Oncology Trading Down 5.3%

KURA stock opened at $9.22 on Friday. The business has a fifty day moving average price of $8.90 and a 200 day moving average price of $9.47. Kura Oncology, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $12.49. The stock has a market capitalization of $818.46 million, a price-to-earnings ratio of -2.75 and a beta of 0.32. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.05.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. The firm had revenue of $18.27 million for the quarter, compared to analyst estimates of $25.97 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%. Analysts expect that Kura Oncology, Inc. will post -3.26 EPS for the current fiscal year.

Trending Headlines about Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Kura emphasized a strong start for KOMZIFTI, noting about $5.8 million in first full launch-quarter sales, which suggests early commercial traction. Kura targets 2028 first top line KOMET-017 Phase III results as KOMZIFTI posts $5.8M in first full launch quarter
• Positive Sentiment: Brokerage commentary remained constructive overall, with Barclays reportedly reiterating a Buy and analysts collectively maintaining a Moderate Buy view. Kura Oncology (KURA) Receives a Buy from Barclays
• Neutral Sentiment: In its Q1 earnings discussion, Kura highlighted the commercial launch of KOMZIFTI and pipeline milestones, including plans for KOMET-017 Phase III topline results in 2028. Kura Oncology Inc (KURA) Q1 2026 Earnings Call Highlights: Strong KOMZIFTI Launch Amid Rising …
• Negative Sentiment: HC Wainwright lowered earnings estimates across several periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, and FY2029, signaling expectations for deeper losses than previously modeled.
• Negative Sentiment: The most recent revisions were especially notable for FY2026 and FY2027, where projected EPS losses widened, reinforcing concerns that profitability remains distant.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.